Gastrointestinal Cancer News

Apixaban appeared to serve as a feasible management option for patients with cancer and venous thromboembolism, according to the results of a subgroup analysis from the AMPLIFY trial.

In team sports, home-field advantage appears to be a real phenomenon. Although the exact causes are not clear — despite having been extensively investigated — there seem to be intangible, difficult-to-define reasons why teams do better in familiar surroundings with a strong support system.

Nausea and vomiting are two of the most distressing and potentially debilitating effects of cancer treatment.

The development of stomatitis in patients taking everolimus did not appear to adversely affect PFS and, thus, should not be considered a hindrance to the drug’s administration, according to the results of a meta-analysis.

The real-world cost of care to treat hepatocellular carcinoma for patients with hepatitis C cirrhosis is very high, according to findings from a retrospective cohort study.

NEW ORLEANS — David Polsky, MD, PhD, professor of dermatology and pathology at NYU School of Medicine and NYU Langone Medical Center, offers insights into advances in liquid biopsy.

Online health information regarding pancreatic cancer often overestimated the reading level of the general population and lacked accurate information about alternative therapeutic options, according to study results published in JAMA Surgery.

Bayer announced results of its phase 3 RESORCE clinical trial, indicating Stivarga improved overall survival in patients with unresectable hepatocellular carcinoma.

The addition of radiation to chemotherapy failed to improve OS for patients with locally advanced pancreatic cancer, according to the results of the randomized, open-label, phase 3 LAP07 trial.

An estimated 746,000 deaths occur annually from liver cancer worldwide.